

00000000000000000000000000000000

— Page 23, line 15, delete “FIG. 3” and insert --FIGS. 3A-3R--.
— Page 23, line 17, delete “FIG. 3” and insert --FIGS. 3A-3R--.
— Page 23, line 19, delete “FIG. 3” and insert --FIGS. 3A-3R--.
— Page 23, line 28, delete “FIG. 3” and insert --FIGS. 3A-3R--.
— Page 23, line 3, delete “FIG. 3” and insert --FIGS. 3A-3R--.
— On page 60, line 4, after “in” delete “6”.
— Page 61, line 11, delete “FIG. 14” and insert --FIGS. 14A-14B--.
— On page 70, line 29, after “in” delete “6”.
— Page 72, line 19, delete “FIG. 17” and insert --FIGS. 17A-17B--.
— Page 75, line 21, delete “FIG. 3. FIG. 3” and insert --FIGS. 3A-3R. FIGS. 3A-3R--.
— Page 75, line 23, delete “FIG. 3” and insert --FIGS. 3A-3R--.
— Page 75, line 26, delete “FIG. 3” and insert --FIGS. 3A-3R--.

Please renumber pages 89-120 of the Claims to be pages 378-409.

Please renumber pages 121-409 of the Appendices to be pages 89-377.

IN THE DRAWINGS

In Figure 6, the bond in the attached red lined figure should be removed. A corrected Figure 6 is submitted and is also submitted as a formal drawing to the Official Draftsperson.

IN THE CLAIMS

Please cancel claims 1-17, 19-40, and 42-60.

Please amend claims 18 and 41 as follows:

18. (Amended) A peptide, peptidomimetic or synthetic [molecule] compound capable of selectively modulating the activity of a thyroid hormone receptor (TR) isoform, identified by the method [of any one of claims 8 or 17,] comprising: modeling test peptide, peptidomimetic or synthetic compounds that fit spatially and preferentially into a TR ligand binding domain (TR LBD) isoform of interest using

a4